Company Overview and News
Following months of negotiations, the United States and China are again on the brink of an all-out trade war. The United States has targeted a flurry of Chinese goods, while China has vowed to respond with tariffs of its own, which could hurt U.S. businesses.
SJIU OLLI AEE SJI BOE CNP ENSG QCOM INTC BA SAM
That means when the economic numbers are on the rise, the U.S. consumer is also on the rise. The Federal Reserve just raised interest rates for the second time this year and it says it will likely raise it two more times in 2018. And instead of rocking the market, the market took it as a positive sign that the 10-year economic doldrums may be at an end. I’ll take it one step at a time.
LW PLNT MMYT PRMW EL LGIH NUS HEAR SAM CENT
Investors in Molson Coors Brewing Co (NYSE:TAP) have to be disappointed so far this year. TAP stock is down more than 22% so far in 2018 and more than 27% over the past 12 months. This is compared to the 4.25% year-to-date gain in the SPDR S&P 500 ETF Trust (NYSEARCA:SPY). While Molson now yields 2.6%, investors have to be asking themselves if it’s time to pass on this brew and look for a more refreshing stock.
TAP STZ.B BUD STZ SAM DEO
Anheuser-Busch InBev SA/NV (BUD - Free Report) , alias AB InBev, has been putting up a dismal show lately, owing to its dismal earnings trend. First-quarter 2018 marked AB InBev’s return to the negative earnings surprise trend, after a beat in the preceding quarter. While solid sales growth and synergies from cost savings continued to aid results, higher sales and marketing expenses ahead of the FIFA World Cup, along with fall in other operating income due to difficult comparisons, were impediments.
IPAR XEL BUD HSC ABI AHBIF SAM
Constellation Brands Inc. (STZ - Free Report) is witnessing spectacular growth lately, driven by its constant brand-building efforts, acquisitions and strength in the beer business. Further, its solid surprise trend and favorable outlook for fiscal 2019 has boosted investors’ confidence on the stock. This led to an upsurge in the stock price, which also hovers close to its 52-week high. The stock has rallied 22.
IPAR STZ.B STZ SAM
Brown-Forman Corporation (BF.B - Free Report) delivered fourth-quarter fiscal 2018 results, wherein both earnings and sales topped estimates. This marked the company’s fourth straight quarter of earnings and sales beat. Adjusted earnings of 23 cents declined 24% but surpassed the Zacks Consensus Estimate of 22 cents. Earnings were hurt by the previously announced creation of a $70 million charitable foundation as well as phasing of operating expenses.
EMN.WS BREW CQP BF.B BF.A EMN LNG BFA SAM
Canopy has recovered from the market correction of the cannabis industry, and seems to be well-positioned to supply the recreational market in Canada after legalization.
STZ.B PM TWMJF ACB BREW ACBFF WEED APHQF STZ CGC SAM
Kaman Corporation (KAMN - Free Report) recently announced that its Aerospace segment has secured its foremost order under Option 14 of its present U.S. Air Force (USAF) Joint Programmable Fuze (JPF) contract. The estimated worth of this deal is $69 million. Kaman has been providing JPF’s to USAF since 2002. The JPF permits the setting of a weapon to be automated in the flight wing and is presently USAF’s preferred bomb fuze.
EMN.WS GGG EMN IEX KAMN AIT SAM
Applied Industrial Technologies, Inc.’s (AIT - Free Report) updated research report was issued on June 4. Over the last year shares of the company have rallied nearly 16.2% on the back of its robust growth drivers. Remaining almost flat in the past few quarters, Applied Industrial’s revenues rebounded in third-quarter fiscal 2018 (ended March 2018). Eliminating acquisition and currency impact, the top line improved 6.
EMN.WS GGG EMN IEX AIT SAM AAXN
Retail REIT Kimco Realty Corp. (KIM - Free Report) is experiencing decent demand for its Mill Station Signature Series Development project. In fact, recently, the company announced addition of a number of retailers to its tenant lineup at this project, including Lowe’s Home Improvement (LOW - Free Report) , Marshalls, TJX’s new HomeSense concept, Burlington and Five Below (FIVE - Free Report) . With these retailers joining Costco and AMC Theatre in the tenant roster, the company has been able to achieve more than 75% of preleasing for this $108-million Signature Series development project.
KIM.PRI EMN.WS SPG.PRJ EMN SPG KIM.PRM FIVE KIM KIM.PRL SAM KIM.PRK KIM.PRJ
Apple (AAPL - Free Report) unveiled new versions of operating system software for iOS, Mac and Watch at Worldwide Developers Conference (WWDC) on Jun 4. The new version of iOS will speed up older phones. This is a notable development considering the “batterygate” fiasco, when Apple was accused of intentionally slowing iPhones with older batteries through software updates. At WWDC, Apple stated that “apps will open up to 40% faster, the onscreen keyboard will appear up to 50% faster and the camera app will open up to 70% faster” in iOS 12.
EMN.WS TXN EMN AAPL NVDA SAM
Typically, most investors don’t actively seek out so-called vice stocks. Due to their controversial businesses or recent scandals, some companies are deemed not worth the trouble to engage with. However, with financial markets entering a phase of fear and uncertainty, any viable alternative is open for consideration.
STZ.B FB PM BTI CHDN AOBC RAI BATS 4162 LB SAM WMT RGR ATVI WVVI DKS MO BGFV EA BUD EFX AOI STZ VSTO RICK
Eastman Chemical Company (EMN - Free Report) will increase the selling prices of Plasticizers. The price hike will be effective from Jul 1, 2018 or as contracts permit. The company will increase the prices of Benzoflex and Versafix Plasticizers by 5 cents per lb each in North and Latin America. Eastman Chemical is taking appropriate pricing actions in response to escalated operating costs including rising raw material costs and freight charges.
EMN.WS EMN FTI.WI FMC CC SAM CE
It was a week where oil prices tumbled to their lowest levels since April. However, natural gas futures edged closer to the psychologically important $3 level.
OPHR SLB RDS.B RDS.A XOM NOV GLNG RDSB VLO RDSA MPC SAM BHI EMN.WS EMN RYDBF SCL SLB RYDAF
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SAM / Boston Beer Company, Inc. (THE) on message board site Silicon Investor.
as of ET